Although the precise mechanism of β2M as a prognostic factor in DLBCL remains unclear, its serum levels reflect its release from the membranes of white blood cells (its primary source) and the cytoplasm of cells, correlating with cell proliferation, thereby serving as a tumor burden marker [62]. The gene discussed is B2M; the disease is diffuse large B-cell lymphoma.